The Food and Drug Administration is seldom accused of being too transparent. But in late September it looked like the agency had overshared. In an attempt to achieve the “greatest level of transparency,” the FDA caused the stock prices of four biotech companies to hemorrhage. Jittery traders, sifting through scraps of context-free information provided by the agency, dumped their drug stocks, triggering a brief but brutal plunge.